Merck & Co., Inc.

RAHWAY, NJ · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$820.3M2026 Q3
Positions13
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.99.9%

Merck & Co., Inc. reported 13 positions worth $820.3M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: MRNA (54.2%).

10 / 13 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 MRNAModerna$444.5M54.18%2,308,190——+11.8%
▸ 2 PSNLPersonalis$228.7M27.87%14,044,943——-9.1%
▸ 3 KYMRKymera Therapeutics$86.3M10.52%772,165——+14.1%
▸ 4 AKTSAktis Oncology$18.6M2.26%952,844——-17.0%
▸ 5 EIKNEikon Therapeutics$13.4M1.63%1,666,666——-33.0%
▸ 6 TRDAEntrada Therapeutics$11.0M1.35%1,739,768——-19.8%
▸ 7 ALECAlector$6.6M0.80%3,545,719——+37.3%
▸ 8 STROSutro Biopharma$4.4M0.54%272,351——-39.0%
▸ 9 EVAXEvaxion A/S$4.0M0.48%1,214,126———
▸ 10 VRDNViridian Therapeutics$1.9M0.23%93,414——+49.9%

Pro Feature

The remaining 3 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Merck & Co., Inc. hold as of Q3 2026?

Merck & Co., Inc. reported 13 positions worth $820.3M in its Q3 2026 13F filing. Largest positions: MRNA (54.2%), PSNL (27.9%), KYMR (10.5%), AKTS (2.3%) and EIKN (1.6%).

What did Merck & Co., Inc. buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Merck & Co., Inc. sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.